These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors. Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495 [TBL] [Abstract][Full Text] [Related]
6. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795 [TBL] [Abstract][Full Text] [Related]
7. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra. Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191 [TBL] [Abstract][Full Text] [Related]
8. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease. Cova L; Bossolasco P; Armentero MT; Diana V; Zennaro E; Mellone M; Calzarossa C; Cerri S; Deliliers GL; Polli E; Blandini F; Silani V Apoptosis; 2012 Mar; 17(3):289-304. PubMed ID: 22160861 [TBL] [Abstract][Full Text] [Related]
10. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024 [TBL] [Abstract][Full Text] [Related]
12. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Levy YS; Bahat-Stroomza M; Barzilay R; Burshtein A; Bulvik S; Barhum Y; Panet H; Melamed E; Offen D Cytotherapy; 2008; 10(4):340-52. PubMed ID: 18574767 [TBL] [Abstract][Full Text] [Related]
13. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Armstrong RJ; Hurelbrink CB; Tyers P; Ratcliffe EL; Richards A; Dunnett SB; Rosser AE; Barker RA Exp Neurol; 2002 May; 175(1):98-111. PubMed ID: 12009763 [TBL] [Abstract][Full Text] [Related]
14. Transplantation of mouse CGR8 embryonic stem cells producing GDNF and TH protects against 6-hydroxydopamine neurotoxicity in the rat. Liu TW; Ma ZG; Zhou Y; Xie JX Int J Biochem Cell Biol; 2013 Jul; 45(7):1265-73. PubMed ID: 23535049 [TBL] [Abstract][Full Text] [Related]
15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539 [TBL] [Abstract][Full Text] [Related]
16. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. Sharma R; McMillan CR; Niles LP J Pineal Res; 2007 Oct; 43(3):245-54. PubMed ID: 17803521 [TBL] [Abstract][Full Text] [Related]
17. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079 [TBL] [Abstract][Full Text] [Related]
18. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Somoza R; Juri C; Baes M; Wyneken U; Rubio FJ Biol Blood Marrow Transplant; 2010 Nov; 16(11):1530-40. PubMed ID: 20542127 [TBL] [Abstract][Full Text] [Related]
19. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043 [TBL] [Abstract][Full Text] [Related]
20. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Rosenblad C; Kirik D; Björklund A Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]